PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — FY2014 Earnings Presentation
21 slides from PT Kalbe Farma Tbk's earnings presentation, February 2015
Slide 1: Analyst Gathering February 2015
Not all collagen is the same, it’s time to choose the right one Analyst Gathering February 2015
Slide 2: Table of Contents
Table of Contents MACRO OVERVIEW 3 BUSINESS OVERVIEW 6 INDICATIVE 2014 RESULTS & 2015 OUTLOOK 14 Excellence in Execution 2
Slide 3: Section 1 Macro Overview
Not all collagen is the same, it’s time to choose the right one Section 1 Macro Overview
Slide 4: Macro Overview
Macro Overview 2014 Macro highlights 2015 Macro outlook Weakening Rupiah, but with less ASEAN Economic Community volatility Rupiah – US Dollar (Exchange Rates on Transaction) 12.5%* • International expansion opportunities • Non tariff barriers in pharma industry *based on average Rising inflation of
Slide 5: Healthcare Industry
Healthcare Industry The new national health insurance roll-out 2014 Highlights • JKN covered more than 133 million people, higher than targeted coverage of 120 million people 2015 Outlook • Integration of formal sector workers into JKN • Discussion of Coordination of Benefits(COB) JKN has been imple
Slide 6: Section 2 Business Overview
Not all collagen is the same, it’s time to choose the right one Section 2 Business Overview
Slide 7: Strategic Intent
Strategic Intent We are an Innovative Health Care Business providing Health Care Products & Its WBAWI Related Services Mission To improve health for a better life To be the best Indonesian Global Health Care company driven by innovation, strong Vision brands and excellent management 1.Sustainable Gr
Slide 8: Our Strategies
Our Strategies 1. Strengthen business portfolio through innovation and M&A 2. Improve marketing and sales effectiveness CORPORATE BRANDING Morinaga Mall to Mall 2014, Diabetasol 3J Campaign attracting more than 288,000 & Healthy Activities in visitors World Diabetes Day Excellence in Execution 8
Slide 9: Our Strategies
Our Strategies 3. Accelerate “Go Global” implementation 4. Develop future leaders with competence and “Kalbe Panca Sradha” character Kalbe Middle Kalbe Learning Management Center Program 5. Strengthen quality assurance, compliance, and corporate social responsibilities Excellence in Execution 9
Slide 10: 2014 Key Achievements & Activities
2014 Key Achievements & Activities Strengthening production and distribution network Started commercial production of Upgraded distribution facilities oncology production facilities at Pulogadung Bandar Lampung Tangerang Increased production lines and capacities Surabaya Excellence in Execution 10
Slide 11: 2014 Key Achievements & Activities
2014 Key Achievements & Activities Strengthening product portfolio through innovation New Product Launches Research & Development Stem Cell and Cancer Institute Excellence in Execution 11
Slide 12: 2014 Key Achievements & Activities
2014 Key Achievements & Activities International expansion Fitbar TV Commercial Diabetasol Product Sampling Woods Winter Wholesale Displays Philippines South Africa Nigeria Myanmar Vietnam Extra Joss Cup Procold Booth & Sponsorship Mixagrip Store Mixagrip Taxi Branding Kalbe Ethical Product Booth -
Slide 13: 2014 Key Achievements & Activities
2014 Key Achievements & Activities Getting closer to our consumers Integrated Service to Consumers Direct to Consumer (DTC) Activities 2014 Kalbe Customer Care Kalbe Home Delivery Kalbe e-Store KALCare Experiential Store Kalbe Family Rewards Card Morinaga Entrasol Mobile Application Utilization Kalb
Slide 14: Section 3 Indicative 2014 Results & 2015 Outlook
Not all collagen is the same, it’s time to choose the right one Section 3 Indicative 2014 Results & 2015 Outlook
Slide 15: Consolidated Sales
Consolidated Sales Consistent Top Line Growth of Internal Kalbe Products Net Sales (in Rp Bn) +8.5% 31 Dec 2013 31 Dec 2014 (Audited) (Unaudited) 17,365 16,002 +20.8% +16.7% +11.9% -5.2% 5,836 5,531 4,329 4,581 3,869 3,792 2,505 2,924 Prescription Consumer Health Nutritionals Distribution & Consolid
Slide 16: Consolidated Operating Performance
Consolidated Operating Performance Stable Operating Margin Gross Profit Margin Operating Expenses to Net Sales Ratios + 10.4% 48.0% 48.8% 32.1% 32.9% 7,679 8,474 0.8% 0.8% 4.8% 5.2% Selling & Marketing 31 Dec 2013 31 Dec 2014 (Audited) (Unaudited) 26.4% 26.9% General & Operating Profit Margin Admini
Slide 17: Consolidated Net Earnings
Consolidated Net Earnings Consistent Earnings Growth Income Before Tax Net Income (in Rp bn) (in Rp bn) + 7.0% 16.1% 15.9% +6.9 % 2,573 2,753 12.0% 11.8% 1,920 2,051 31 Dec 2013 31 Dec 2014 31 Dec 2013 31 Dec 2014 (Audited) (Unaudited) (Audited) (Unaudited) • Income before tax margin declined from 1
Slide 18: Working Capital Management
Working Capital Management Improving Days of Inventory Improving inventory level due 158 to stabilizing raw material price No. of days in 2014 129 131 120 129 142 108 114 132 122 126 110 115 107 Net Operating Cycle has been decreased by 29 days from 158 50 49 days in 2008 to 129 days in 43 45 44 48
Slide 19: Solid Financial Position
Solid Financial Position Rp 1.62 Trillion of Net Cash Position Total Debt and Gearing Ratio Cash & Net Cash Balance 2,291 2,151 1,919 1,902 1,877 1,860 1,562 1,655 1,426 1,623 600 15.0% 1,222 500 Total Debt in Rp Billion 7.9% 7.2% 843 400 Gearing Ratio 10.0% 300 2.9% 3.2% 200 2.3% 5.0% 0.5% 100 340
Slide 20: Outlook 2015
Outlook 2015 Earnings Guidance 2015 * 1. Year-on-year Sales Growth 11% - 13% 2. Operating Profit Margin 16% - 17% 3. Earnings per Share growth of 14% - 16% 4. Dividend payout ratio minimum 50% * Excluding the impact of product recall Capex Rp 1 – 1.3 Tn for production capacity and distribution netwo
Slide 21: THANK YOU
THANK YOU For further information: PT Kalbe Farma Tbk. Jalan Let.Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email : vidjongtius@kalbe.co.id kartika.setiabudy@kalbe.co.id investor.relations@kalbe.co.id Website : www.kalbe.co.id Excellence in Execution 2